{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:04:33Z","timestamp":1791338673177,"version":"4.3.1"},"reference-count":27,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The addition of rituximab to the chemotherapy backbone was shown to significantly improve outcomes of children with aggressive high-grade lymphomas in high-income countries. However, data on its safety and efficacy in children with Epstein-Barr virus (EBV)\u2013positive Burkitt lymphoma (BL) are limited. We conducted a prospective nonrandomized observational study in East African patients aged \u226425 years with confirmed BL. Patients received either the International Network for Cancer Treatment and Research (INCTR)\u2013based standard chemotherapy (cyclophosphamide, vincristine, and methotrexate [COM]) or rituximab plus standard chemotherapy (R-COM). The primary end point was safety. The secondary outcomes were event-free and overall survival and cost-effectiveness of incorporating rituximab. Primary analyses were conducted in the intention-to-treat population. The median follow-up was 23 months. Safety analyses included 72 patients: 32 in the COM group and 40 in the R-COM group. Grade \u22653 adverse events occurred in 18% of R-COM patients and 16% of COM patients. With respect to treatment outcomes at 12 months, 5 events were observed in the R-COM group and 14 in the COM group. The 12-month event-free survival was 67% with R-COM and 43% with COM (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.24-0.98; P = .045). There were 8 deaths in the R-COM group, whereas 16 patients died in the COM group (HR, 0.32; 95% CI, 0.14-0.75; P = .009). R-COM was particularly effective in advanced-stage disease. The addition of rituximab to the INCTR-based protocol (COM) for EBV-positive BL has been observed to be safe and feasible in experienced centers in East Africa and saves lives.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015234","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:01:36Z","timestamp":1740171696000},"page":"2393-2401","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Rituximab for children with EBV-positive Burkitt lymphoma in East Africa"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-7551","authenticated-orcid":false,"given":"William Frank","family":"Mawalla","sequence":"first","affiliation":[{"name":"1Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Achola","sequence":"additional","affiliation":[{"name":"2Oncology Unit, St Mary's Hospital Lacor, Gulu, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadijah","family":"Nabalende","sequence":"additional","affiliation":[{"name":"2Oncology Unit, St Mary's Hospital Lacor, Gulu, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8000-9483","authenticated-orcid":false,"given":"Isaac","family":"Otim","sequence":"additional","affiliation":[{"name":"2Oncology Unit, St Mary's Hospital Lacor, Gulu, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6118-542X","authenticated-orcid":false,"given":"Ismail D.","family":"Legason","sequence":"additional","affiliation":[{"name":"2Oncology Unit, St Mary's Hospital Lacor, Gulu, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4178-2809","authenticated-orcid":false,"given":"Martin D.","family":"Ogwang","sequence":"additional","affiliation":[{"name":"2Oncology Unit, St Mary's Hospital Lacor, Gulu, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1979-8396","authenticated-orcid":false,"given":"Pamella M.","family":"Aol","sequence":"additional","affiliation":[{"name":"2Oncology Unit, St Mary's Hospital Lacor, Gulu, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-0991","authenticated-orcid":false,"given":"Godlove","family":"Sandi","sequence":"additional","affiliation":[{"name":"3Paediatric Oncology Unit, Muhimbili National Hospital, Dar es Salaam, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6501-535X","authenticated-orcid":false,"given":"Hadija","family":"Mwamtemi","sequence":"additional","affiliation":[{"name":"3Paediatric Oncology Unit, Muhimbili National Hospital, Dar es Salaam, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salama","family":"Mahawi","sequence":"additional","affiliation":[{"name":"3Paediatric Oncology Unit, Muhimbili National Hospital, Dar es Salaam, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5938-5628","authenticated-orcid":false,"given":"Elifuraha","family":"Mkwizu","sequence":"additional","affiliation":[{"name":"4Cancer Care Centre, Kilimanjaro Christian Medical Centre, Moshi, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philomena G.","family":"Lyamuya","sequence":"additional","affiliation":[{"name":"4Cancer Care Centre, Kilimanjaro Christian Medical Centre, Moshi, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline P.","family":"Kamanga","sequence":"additional","affiliation":[{"name":"5Department of Oncology, Bugando Medical Centre, Mwanza, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6433-6174","authenticated-orcid":false,"given":"Kristin","family":"Schroeder","sequence":"additional","affiliation":[{"name":"5Department of Oncology, Bugando Medical Centre, Mwanza, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ntemi","sequence":"additional","affiliation":[{"name":"5Department of Oncology, Bugando Medical Centre, Mwanza, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5154-7872","authenticated-orcid":false,"given":"Clara","family":"Chamba","sequence":"additional","affiliation":[{"name":"1Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-1507","authenticated-orcid":false,"given":"Dimitris","family":"Vavoulis","sequence":"additional","affiliation":[{"name":"6Department of Oncology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-1795","authenticated-orcid":false,"given":"Liz","family":"Morrell","sequence":"additional","affiliation":[{"name":"7Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Chirande","sequence":"additional","affiliation":[{"name":"1Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3938-8490","authenticated-orcid":false,"given":"Anna","family":"Schuh","sequence":"additional","affiliation":[{"name":"1Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania"},{"name":"6Department of Oncology, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"1","key":"2025052708270106300_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13027-019-0236-7","article-title":"The burden of Burkitt lymphoma in Africa","volume":"14","author":"H\u00e4mmerl","year":"2019","journal-title":"Infect Agent Cancer"},{"key":"2025052708270106300_bib2","doi-asserted-by":"crossref","first-page":"1103737","DOI":"10.3389\/fviro.2023.1103737","article-title":"Malignancy and viral infections in Sub-Saharan Africa: a review","author":"Diakite","year":"2023","journal-title":"Front Virol"},{"key":"2025052708270106300_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ebiom.2018.12.041","article-title":"Epstein-Barr virus, malaria and endemic Burkitt lymphoma","volume":"39","author":"Velavan","year":"2019","journal-title":"EBioMedicine"},{"issue":"24","key":"2025052708270106300_bib4","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1182\/blood-2012-12-475558","article-title":"Trends in survival of patients with Burkitt lymphoma\/leukemia in the USA: an analysis of 3691 cases","volume":"121","author":"Costa","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2025052708270106300_bib5","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2025052708270106300_bib6","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.bcmd.2004.08.001","article-title":"Report of an International Network of Cancer Treatment and Research workshop on non-Hodgkin\u2019s lymphoma in developing countries","volume":"33","author":"Naresh","year":"2004","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"2025052708270106300_bib7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2141.2012.09236.x","article-title":"Treatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent disease","volume":"158","author":"Ngoma","year":"2012","journal-title":"Br J Haematol"},{"issue":"5","key":"2025052708270106300_bib8","first-page":"1","article-title":"Advanced Burkitt lymphoma in Sub-Saharan Africa pediatric units: results of the third prospective multicenter study of the Groupe Franco-Africain d\u2019Oncologie P\u00e9diatrique","volume":"5","author":"Bouda","year":"2019","journal-title":"J Glob Oncol"},{"issue":"6","key":"2025052708270106300_bib9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bjh.14716","article-title":"Dissecting heterogeneous outcomes for paediatric Burkitt lymphoma in Malawi after anthracycline-based treatment","volume":"181","author":"Westmoreland","year":"2018","journal-title":"Br J Haematol"},{"issue":"5","key":"2025052708270106300_bib10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/bjh.13986","article-title":"Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi","volume":"173","author":"Stanley","year":"2016","journal-title":"Br J Haematol"},{"issue":"16","key":"2025052708270106300_bib11","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/bloodadvances.2020002178","article-title":"Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa","volume":"4","author":"Ozuah","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2025052708270106300_bib12","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"8","key":"2025052708270106300_bib13","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt\u2019s lymphoma: results of United Kingdom Lymphoma Group LY06 study","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol"},{"issue":"20","key":"2025052708270106300_bib14","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt\u2019s lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"2025052708270106300_bib15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2020006926","article-title":"Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers","volume":"137","author":"Evens","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2025052708270106300_bib16","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1182\/blood-2021-146036","article-title":"Outcomes in relapsed\/refractory Burkitt lymphoma: a multi-centre Canadian experience","volume":"138","author":"Manji","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2025052708270106300_bib17","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.24720","article-title":"Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia\/lymphoma","volume":"92","author":"Short","year":"2017","journal-title":"Am J Hematol"},{"issue":"10","key":"2025052708270106300_bib18","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1038\/s41375-021-01256-8","article-title":"A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma","volume":"35","author":"Goldman","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"2025052708270106300_bib19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.13040","article-title":"Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive Burkitt lymphoma\/leukaemia: a Children\u2019s Oncology Group report","volume":"167","author":"Goldman","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"2025052708270106300_bib20","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2012.255","article-title":"Rituximab and FAB\/LMB 96 chemotherapy in children with stage III\/IV B-cell non-Hodgkin lymphoma: a Children\u2019s Oncology Group report","volume":"27","author":"Goldman","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"2025052708270106300_bib21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/his.14594","article-title":"A refined approach to the diagnosis of Burkitt lymphoma in a resource-poor setting","volume":"80","author":"Naresh","year":"2022","journal-title":"Histopathology"},{"issue":"6","key":"2025052708270106300_bib22","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1365-2141.2011.08771.x","article-title":"Diagnosis of Burkitt lymphoma using an algorithmic approach \u2013 applicable in both resource-poor and resource-rich countries","volume":"154","author":"Naresh","year":"2011","journal-title":"Br J Haematol"},{"issue":"7","key":"2025052708270106300_bib23","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1016\/S2214-109X(21)00181-9","article-title":"Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1\/2 clinical trial","volume":"9","author":"Kimani","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"1","key":"2025052708270106300_bib24","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1038\/s41598-017-05713-2","article-title":"Viral driven epigenetic events alter the expression of cancer-related genes in Epstein-Barr-virus naturally infected Burkitt lymphoma cell lines","volume":"7","author":"Hernandez-Vargas","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"2025052708270106300_bib25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2014.10.017","article-title":"Differential proteomic analysis of endemic and sporadic Epstein-Barr virus-positive and negative Burkitt lymphoma","volume":"51","author":"El-Mallawany","year":"2015","journal-title":"Eur J Cancer"},{"issue":"2","key":"2025052708270106300_bib26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10198-023-01581-y","article-title":"Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin\u2019s lymphoma","volume":"25","author":"Lueza","year":"2024","journal-title":"Eur J Health Econ"},{"issue":"9","key":"2025052708270106300_bib27","doi-asserted-by":"crossref","first-page":"e1305","DOI":"10.1016\/S2214-109X(21)00261-8","article-title":"Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis","volume":"9","author":"Painschab","year":"2021","journal-title":"Lancet Glob Health"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2393\/2374433\/blooda_adv-2024-015234-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/10\/2393\/2374433\/blooda_adv-2024-015234-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:27:13Z","timestamp":1748348833000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/10\/2393\/535658\/Rituximab-for-children-with-EBV-positive-Burkitt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,5,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015234","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,27]]},"published":{"date-parts":[[2025,5,14]]}}}